Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
03 sept. 2024 08h02 HE
|
Pasithea
Pasithea Tx appoints Dr. Rebecca Brown, an expert in Neurofibromatosis and Director at Mount Sinai, to its Scientific Advisory Board to aid in PAS-004.
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
24 avr. 2024 07h59 HE
|
Pasithea
Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
13 févr. 2024 07h59 HE
|
Pasithea
Pasithea Tx activates four U.S. sites for Phase 1 Trial of its next-gen MEK inhibitor, aiming to assess safety, efficacy, and biomarker data.
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
08 janv. 2024 07h59 HE
|
Pasithea
Pasithea Therapeutics unveils crystalline PAS-004, extending IP protection to 2045 for CNS disorder treatments.
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
02 janv. 2024 08h35 HE
|
Pasithea
Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3.
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
19 déc. 2023 17h19 HE
|
Pasithea
Disclosure related to the annual meeting of Pasithea Therapeutics (Nasdaq: KTTA)
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
11 déc. 2023 08h01 HE
|
Pasithea
Pasithea Therapeutics (Nasdaq: KTTA) announced positive preclinical efficacy in models conducted ahead of its planned Phase I, in-human trials in 1Q24.
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
29 nov. 2023 16h27 HE
|
Pasithea
Pasithea Therapeutics adjourns 2023 annual meeting of stockholders.
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
09 nov. 2023 07h59 HE
|
Pasithea
Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
14 sept. 2023 08h30 HE
|
Pasithea
PALO ALTO, Calif. and MIAMI, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research,...